37 results on '"Toyoda, Yu"'
Search Results
2. Functional characterization of variants in human ABCC11, an axillary osmidrosis risk factor.
- Author
-
Toyoda, Yu, Matsuo, Hirotaka, and Takada, Tappei
- Subjects
ATP-binding cassette transporters ,APOCRINE glands ,BIOCHEMICAL variation ,CELL physiology ,CELL membranes ,DRUG toxicity - Abstract
Human ATP-binding cassette transporter C11 (ABCC11) is a membrane protein exhibiting ATP-dependent transport activity for a variety of lipophilic anions including endogenous substances and xenobiotics such as anti-cancer agents. Accumulating evidence indicates that ABCC11 wild type is responsible for the high-secretion phenotypes in human apocrine glands including wet type of earwax and the risk of axillary osmidrosis. Also, a less-functional variant of ABCC11 was reportedly associated with a risk for drug-induced toxicity in humans. Thus, functional change in ABCC11 may affect individual's constitution and drug toxicity, which led us to reason that functional validation of genetic variations in ABCC11 should be of importance. Therefore, in addition to p.G180R (a well-characterized non-functional variant of ABCC11), we studied cellular expression and function of 10 variants of ABCC11. In this study, ABCC11 function was evaluated as an ATP-dependent transport of radio labeled-dehydroepiandrosterone sulfate using ABCC11-expressing plasma membrane vesicles. Except for p.G180R, other 10 variants were maturated as an N-linked glycoprotein and expressed on the plasma membrane. We found that six variants impaired the net cellular function of ABCC11. Among them, p.R630W was most influential. Including this identification of a significantly-dysfunctional variant, our findings will extend our understanding of genetic variations and biochemical features of ABCC11 protein. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Regulation of Urate Homeostasis by Membrane Transporters.
- Author
-
Takada, Tappei, Miyata, Hiroshi, Toyoda, Yu, Nakayama, Akiyoshi, Ichida, Kimiyoshi, and Matsuo, Hirotaka
- Subjects
ORGANIC anion transporters ,MEMBRANE transport proteins ,URATES ,ATP-binding cassette transporters ,HOMEOSTASIS ,CARRIER proteins ,GLUCOSE transporters - Abstract
Uric acid is the final purine metabolite in humans. Serum urate levels are regulated by a balance between urate production, mainly in the liver, and its excretion via the kidneys and small intestine. Given that uric acid exists as a urate anion at physiological pH 7.4, membrane transporters are required to regulate urate homeostasis. In the kidney, urate transporter 1, glucose transporter 9, and organic anion transporter 10 contribute to urate reabsorption, whereas sodium-dependent phosphate transport protein 1 would be involved in urate excretion. Other transporters have been suggested to be involved in urate handling in the kidney; however, further evidence is required in humans. ATP-binding cassette transporter G2 (ABCG2) is another urate transporter, and its physiological role as a urate exporter is highly demonstrated in the intestine. In addition to urate, ABCG2 regulates the behavior of endogenous substances and drugs; therefore, the functional inhibition of ABCG2 has physiological and pharmacological effects. Although these transporters explain a large part of the urate regulation system, they are not sufficient for understanding the whole picture of urate homeostasis. Therefore, numerous studies have been conducted to find novel urate transporters. This review provides the latest evidence of urate transporters from pathophysiological and clinical pharmacological perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Dysuricemia.
- Author
-
Nakayama, Akiyoshi, Kurajoh, Masafumi, Toyoda, Yu, Takada, Tappei, Ichida, Kimiyoshi, and Matsuo, Hirotaka
- Subjects
CHRONIC kidney failure ,URIC acid ,ACUTE kidney failure ,REACTIVE oxygen species ,CARDIOVASCULAR diseases ,XANTHINE - Abstract
Gout results from elevated serum urate (SU) levels, or hyperuricemia, and is a globally widespread and increasingly burdensome disease. Recent studies have illuminated the pathophysiology of gout/hyperuricemia and its epidemiology, diagnosis, treatment, and complications. The genetic involvement of urate transporters and enzymes is also proven. URAT1, a molecular therapeutic target for gout/hyperuricemia, was initially derived from research into hereditary renal hypouricemia (RHUC). RHUC is often accompanied by complications such as exercise-induced acute kidney injury, which indicates the key physiological role of uric acid. Several studies have also revealed its physiological role as both an anti-oxidant and a pro-oxidant, acting as both a scavenger and a generator of reactive oxygen species (ROSs). These discoveries have prompted research interest in SU and xanthine oxidoreductase (XOR), an enzyme that produces both urate and ROSs, as status or progression biomarkers of chronic kidney disease and cardiovascular disease. The notion of "the lower, the better" is therefore incorrect; a better understanding of uric acid handling and metabolism/transport comes from an awareness that excessively high and low levels both cause problems. We summarize here the current body of evidence, demonstrate that uric acid is much more than a metabolic waste product, and finally propose the novel disease concept of "dysuricemia" on the path toward "normouricemia", or optimal SU level, to take advantage of the dual roles of uric acid. Our proposal should help to interpret the spectrum from hypouricemia to hyperuricemia/gout as a single disease category. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Biochemical characterization of Jr(a−) blood type‐related ABCG2 variants: Arg147Trp and Ser572Arg disrupt the plasma membrane localization of ABCG2.
- Author
-
Toyoda, Yu, Matsuo, Hirotaka, Tanaka, Mitsunobu, Stiburkova, Blanka, and Takada, Tappei
- Subjects
CELL membranes ,ATP-binding cassette transporters ,SINGLE nucleotide polymorphisms ,BLOOD group antigens ,NUCLEIC acids ,BLOOD groups - Abstract
This article discusses the genetic associations between the Jr(a-) blood type and mutations in the ABCG2 gene. The ABCG2 gene is known as a membrane transporter that regulates the pharmacokinetics of drugs and also serves as an antigen in the JR blood group system. The study provides biochemical evidence that two rare variants of ABCG2, p.R147W and p.S572R, disrupt the plasma membrane localization of the ABCG2 protein, which is believed to be the cause of the Jr(a-) blood type. This information is important for understanding the effects of these genetic variations on drug safety and efficacy, as well as transfusion reactions related to the Jr(a-) blood type. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
6. Vitamin C transporter SVCT1 serves a physiological role as a urate importer: functional analyses and in vivo investigations.
- Author
-
Toyoda, Yu, Miyata, Hiroshi, Uchida, Naohiro, Morimoto, Keito, Shigesawa, Ryuichiro, Kassai, Hidetoshi, Nakao, Kazuki, Tomioka, Naoko H., Matsuo, Hirotaka, Ichida, Kimiyoshi, Hosoyamada, Makoto, Aiba, Atsu, Suzuki, Hiroshi, and Takada, Tappei
- Subjects
VITAMIN C ,FUNCTIONAL analysis ,AMINO acid sequence ,KNOCKOUT mice ,ANTIOXIDANTS ,URIC acid - Abstract
Uric acid, the end product of purine metabolism in humans, is crucial because of its anti-oxidant activity and a causal relationship with hyperuricemia and gout. Several physiologically important urate transporters regulate this water-soluble metabolite in the human body; however, the existence of latent transporters has been suggested in the literature. We focused on the Escherichia coli urate transporter YgfU, a nucleobase-ascorbate transporter (NAT) family member, to address this issue. Only SLC23A proteins are members of the NAT family in humans. Based on the amino acid sequence similarity to YgfU, we hypothesized that SLC23A1, also known as sodium-dependent vitamin C transporter 1 (SVCT1), might be a urate transporter. First, we identified human SVCT1 and mouse Svct1 as sodium-dependent low-affinity/high-capacity urate transporters using mammalian cell-based transport assays. Next, using the CRISPR-Cas9 system followed by the crossing of mice, we generated Svct1 knockout mice lacking both urate transporter 1 and uricase. In the hyperuricemic mice model, serum urate levels were lower than controls, suggesting that Svct1 disruption could reduce serum urate. Given that Svct1 physiologically functions as a renal vitamin C re-absorber, it could also be involved in urate re-uptake from urine, though additional studies are required to obtain deeper insights into the underlying mechanisms. Our findings regarding the dual-substrate specificity of SVCT1 expand the understanding of urate handling systems and functional evolutionary changes in NAT family proteins. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. SNP-based heritability estimates of gout and its subtypes determined by genome-wide association studies of clinically defined gout.
- Author
-
Toyoda, Yu, Nakatochi, Masahiro, Nakayama, Akiyoshi, Kawamura, Yusuke, Nakaoka, Hirofumi, Wakai, Kenji, Matsuo, Keitaro, Matsuo, Hirotaka, and Consortium, for the Japan Gout Genomics
- Subjects
SINGLE nucleotide polymorphisms ,GENOMES ,DISEASE susceptibility ,GOUT - Abstract
The article discusses research which investigated the heritability estimates of gout, including its subtypes, in Japanese populations via genome-wide association study (GWS) meta-analyses. Cited are the findings of the investigation on single nucleotidepolymorphism (SNP)-based heritability of three major subtypes of gout, the estimated polygenetic contributions to the heritability of gout, and results indicating that genetic factors are contributors to individual variability in gout.
- Published
- 2023
- Full Text
- View/download PDF
8. Coffee Consumption Reduces Gout Risk Independently of Serum Uric Acid Levels: Mendelian Randomization Analyses Across Ancestry Populations.
- Author
-
Shirai, Yuya, Nakayama, Akiyoshi, Kawamura, Yusuke, Toyoda, Yu, Nakatochi, Masahiro, Shimizu, Seiko, Shinomiya, Nariyoshi, Okada, Yukinori, and Matsuo, Hirotaka
- Subjects
URIC acid ,GOUT ,GENOME-wide association studies ,COFFEE ,JAPANESE people - Abstract
Objective: The effects of coffee consumption on serum uric acid (SUA) levels and gout risk are controversial. There have hitherto been no reports based on Mendelian randomization (MR) analysis of its effects that consider pleiotropy. Here, we evaluated the effects of coffee consumption across ancestry populations, taking pleiotropy into account. Methods: We performed the first MR analyses for coffee consumption on SUA levels and gout, considering pleiotropy. We used the following summary statistics of genome‐wide association studies from a Japanese population: habitual coffee consumption (152,634 subjects), gout (3053 cases and 4554 controls), and SUA levels (121,745 subjects). In addition to fixed‐effect inverse variance weighted (IVW) meta‐analysis, we performed a robust evaluation of heterogeneity and removed several instruments for reasons of possible pleiotropy. Previous European datasets were also reevaluated while heterogeneity was considered. Results: Habitual coffee consumption was significantly and inversely associated with gout (odds ratio [OR] = 0.29, 95% confidence interval [95% CI]: 0.16‐0.51, P = 1.9 × 10−5) in random‐effect IVW (Phet = 5.5 × 10−19). Excluding pleiotropic instruments, the protective effect on gout was confirmed in fixed‐effect IVW analysis (OR = 0.75, 95% CI: 0.58‐0.97, P = 0.026) without heterogeneity (Phet = 0.39). However, we observed no significance in the previous European datasets when heterogeneity was considered. Associations were not observed between coffee consumption and SUA levels in either ancestry in MR analyses that considered pleiotropy. Multivariable MR analysis showed that increased coffee consumption significantly reduced gout risk, even after adjusting for SUA levels (OR = 0.50, 95% CI: 0.31‐0.81, P = 0.0046). Conclusion: With pleiotropy taken into account, our MR analyses revealed that coffee consumption can causally reduce gout risk, and that it may reduce gout risk independently of SUA levels. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts.
- Author
-
Toyoda, Yu, Kawamura, Yusuke, Nakayama, Akiyoshi, Morimoto, Keito, Shimizu, Seiko, Tanahashi, Yuki, Tamura, Takashi, Kondo, Takaaki, Kato, Yasufumi, Ichida, Kimiyoshi, Suzuki, Hiroshi, Shinomiya, Nariyoshi, Kobayashi, Yasushi, Takada, Tappei, and Matsuo, Hirotaka
- Subjects
FUNCTIONAL analysis ,JAPANESE people ,LOCUS (Genetics) ,ORGANIC anion transporters ,DRUG target ,IMMUNOHISTOCHEMISTRY - Abstract
Dysfunctional missense variant of organic anion transporter 10 (OAT10 / SLC22A13), rs117371763 (c.1129C>T; p.R377C), is associated with a lower susceptibility to gout. OAT10 is a urate transporter; however, its physiological role in urate handling remains unclear. We hypothesized that OAT10 could be a renal urate re-absorber that will be a new molecular target of urate-lowering therapy like urate transporter 1 (URAT1, a physiologically-important well-known renal urate re-absorber) and aimed to examine the effect of OAT10 dysfunction on renal urate handling. For this purpose, we conducted quantitative trait locus analyses of serum urate and fractional excretion of uric acid (FE
UA ) using samples obtained from 4,521 Japanese males. Moreover, we performed immunohistochemical and functional analyses to assess the molecular properties of OAT10 as a renal urate transporter and evaluated its potential interaction with urate-lowering drugs. Clinico-genetic analyses revealed that carriers with the dysfunctional OAT10 variant exhibited significantly lower serum urate levels and higher FEUA values than the non-carriers, indicating that dysfunction of OAT10 increases renal urate excretion. Given the results of functional assays and immunohistochemical analysis demonstrating the expression of human OAT10 in the apical side of renal proximal tubular cells, our data indicate that OAT10 is involved in the renal urate reabsorption in renal proximal tubules from urine. Additionally, we found that renal OAT10 inhibition might be involved in the urate-lowering effect of losartan and lesinurad which exhibit uricosuric effects; indeed, losartan, an approved drug, inhibits OAT10 more strongly than URAT1. Accordingly, OAT10 can be a novel potential molecular target for urate-lowering therapy. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Genetic epidemiological analysis of hypouricaemia from 4993 Japanese on non-functional variants of URAT1/SLC22A12 gene.
- Author
-
Nakayama, Akiyoshi, Kawamura, Yusuke, Toyoda, Yu, Shimizu, Seiko, Kawaguchi, Makoto, Aoki, Yuka, Takeuchi, Kenji, Okada, Rieko, Kubo, Yoko, Imakiire, Toshihiko, Iwasawa, Satoko, Nakashima, Hiroshi, Tsunoda, Masashi, Ito, Keiichi, Kumagai, Hiroo, Takada, Tappei, Ichida, Kimiyoshi, Shinomiya, Nariyoshi, and Matsuo, Hirotaka
- Subjects
GENETIC mutation ,ALLELES ,GENOTYPES ,GENES ,URIC acid ,GENETIC techniques ,LOGISTIC regression analysis - Abstract
Objectives Up to 0.3% of Japanese have hypouricaemia. Most cases appear to result from a hereditary disease, renal hypouricaemia (RHUC), which causes exercise-induced acute kidney injury and urolithiasis. However, to what extent RHUC accounts for hypouricaemia is not known. We therefore investigated its frequency and evaluated its risks by genotyping a general Japanese population. Methods A cohort of 4993 Japanese was examined by genotyping the non-functional variants R90H (rs121907896) and W258X (rs121907892) of URAT1/SLC22A12 , the two most common causative variants of RHUC in Japanese. Results Participants' fractional excretion of uric acid and risk allele frequencies markedly increased at lower serum uric acid (SUA) levels. Ten participants (0.200%) had an SUA level ≤2.0 mg/dl and nine had R90H or W258X and were likely to have RHUC. Logistic regression analysis revealed these URAT1 variants to be significantly and independently associated with the risk of hypouricaemia and mild hypouricaemia (SUA ≤3.0 mg/dl) as well as sex, age and BMI, but these URAT1 variants were the only risks in the hypouricaemia population (SUA ≤2.0 mg/dl). W258X was only a risk in males with SUA ≤3.0 mg/dl. Conclusion Our study accurately reveals the prevalence of RHUC and provides genetic evidence for its definition (SUA ≤2.0 mg/dl). We also show that individuals with SUA ≤3.0 mg/dl, especially males, are prone to RHUC. Our findings will help to promote a better epidemiological understanding of RHUC as well as more accurate diagnosis, especially in males with mild hypouricaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. A meta-analysis of genome-wide association studies using Japanese and Taiwanese has revealed novel loci associated with gout susceptibility.
- Author
-
Chang, Shun-Jen, Toyoda, Yu, Kawamura, Yusuke, Nakamura, Takahiro, Nakatochi, Masahiro, Nakayama, Akiyoshi, Liao, Wei-Ting, Shimizu, Seiko, Takada, Tappei, Takeuchi, Kenji, Wakai, Kenji, Shi, Yongyong, Shinomiya, Nariyoshi, Chen, Chung-Jen, Li, Changgui, Okada, Yukinori, Ichida, Kimiyoshi, Matsuo, Hirotaka, for Japan Gout Genomics Consortium (Japan Gout), and Shirai, Yuya
- Subjects
GENOME-wide association studies ,TYPE 2 diabetes ,GOUT ,LOCUS (Genetics) ,TAIWANESE people ,EAST Asians - Abstract
References 1 Nakayama A, Nakatochi M, Kawamura Y. Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients. Regarding the 11 SNPs potentially associated with gout, we obtained association summary statistics data of the SNPs from the published two GWASs and combined them. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
12. Association Between Earwax-Determinant Genotypes and Acquired Middle Ear Cholesteatoma in a Japanese Population.
- Author
-
Hara, Satoshi, Kusunoki, Takeshi, Nakagawa, Hiroshi, Toyoda, Yu, Nojiri, Shuko, Kamiya, Kazusaku, Furukawa, Masayuki, Takata, Yusuke, Okada, Hiroko, Anzai, Takashi, Matsumoto, Fumihiko, and Ikeda, Katsuhisa
- Abstract
Objective: A single-nucleotide polymorphism 538G>A in the human ABCC11 gene is a determinant of the earwax morphotype. ABCC11 538GG and GA correspond to wet earwax and 538AA to dry earwax. Despite a putative positive correlation between the frequency of the 538G allele and the prevalence of cholesteatoma, minimal clinical information is currently available. We aimed to evaluate this association between the ABCC11 genotypes and acquired middle ear cholesteatoma. Study Design: Case-control study. Setting: Single-center academic hospital. Methods: We recruited 67 Japanese patients with acquired middle ear cholesteatoma (cholesteatoma group) and 100 Japanese controls with no history of middle ear cholesteatoma. We assessed the ABCC11 genotypes for all participants. Clinical information was collected from the cholesteatoma group. The genotype data of 104 Japanese people from the 1000 Genomes Project who represent the general population were used. Results: The proportion of participants with ABCC11 538GG or GA was significantly higher in the cholesteatoma group than in the control group or general Japanese population (P <.001). The ABCC11 538G allele frequency was also significantly higher in the cholesteatoma group than in the control group or general Japanese population (P <.001). Multivariate logistic regression analyses revealed a significant association between the ABCC11 genotype and acquired middle ear cholesteatoma (odds ratio, 5.49; 95% CI, 2.61-11.5; P <.001). Conclusion: Our results suggest that the ABCC11 genotypes could be associated with the development of acquired middle ear cholesteatoma among Japanese people. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12.
- Author
-
Toyoda, Yu, Kawamura, Yusuke, Nakayama, Akiyoshi, Nakaoka, Hirofumi, Higashino, Toshihide, Shimizu, Seiko, Ooyama, Hiroshi, Morimoto, Keito, Uchida, Naohiro, Shigesawa, Ryuichiro, Takeuchi, Kenji, Inoue, Ituro, Ichida, Kimiyoshi, Suzuki, Hiroshi, Shinomiya, Nariyoshi, Takada, Tappei, and Matsuo, Hirotaka
- Subjects
PROTEINS ,HYPERURICEMIA ,ANALYSIS of variance ,PHYLOGENY ,SEQUENCE analysis ,INDIVIDUALIZED medicine ,CELLULAR signal transduction ,FUNCTIONAL assessment ,GENES ,GENE expression profiling ,MEMBRANE transport proteins ,DISEASE susceptibility ,DESCRIPTIVE statistics ,URIC acid ,MEMBRANE proteins ,DATA analysis software ,GOUT ,CARRIER proteins ,CAUSALITY (Physics) ,DISEASE risk factors - Abstract
Objectives Gout, caused by chronic elevation of serum uric acid levels, is the commonest form of inflammatory arthritis. The causative effect of common and rare variants of ATP-binding cassette transporter G2 (ABCG2/BCRP) on gout risk has been studied, but little attention has been paid to the effect of common (rs121907892, p.W258X) and rare variants of urate transporter 1 (URAT1/SLC22A12) on gout, despite dysfunctional variants of URAT1 having been identified as pathophysiological causes of renal hypouricaemia. Methods To address this important but overlooked issue, we investigated the effects of these URAT1 variants on gout susceptibility, using targeted exon sequencing on 480 clinically defined gout cases and 480 controls of Japanese males in combination with a series of functional analyses of newly identified URAT1 variants. Results Our results show that both common and rare dysfunctional variants of URAT1 markedly decrease the risk of gout (OR 0.0338, reciprocal OR 29.6, P = 7.66 × 10
−8 ). Interestingly, we also found that the URAT1 -related protective effect on gout eclipsed the ABCG2 -related causative effect (OR 2.30–3.32). Our findings reveal only one dysfunctional variant of URAT1 to have a substantial anti-gout effect, even in the presence of causative variants of ABCG2 , a 'gout gene'. Conclusion Our findings provide a better understanding of gout/hyperuricaemia and its aetiology that is highly relevant to personalized health care. The substantial anti-gout effect of common and rare variants of URAT1 identified in the present study support the genetic concept of a 'Common Disease, Multiple Common and Rare Variant' model. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach.
- Author
-
Ogura, Masatsune, Toyoda, Yu, Sakiyama, Masayuki, Kawamura, Yusuke, Nakayama, Akiyoshi, Yamanashi, Yoshihide, Takada, Tappei, Shimizu, Seiko, Higashino, Toshihide, Nakajima, Mayuko, Naito, Mariko, Hishida, Asahi, Kawai, Sayo, Okada, Rieko, Sasaki, Makoto, Ayaori, Makoto, Suzuki, Hiroshi, Takata, Koki, Ikewaki, Katsunori, and Harada-Shiba, Mariko
- Subjects
URIC acid ,KNOCKOUT mice ,MULTIPLE regression analysis ,APOLIPOPROTEIN E ,JAPANESE people ,CHLOROPLAST DNA - Abstract
Elevated serum uric acid (SUA)—hyperuricemia—is caused by overproduction of urate or by its decreased renal and/or intestinal excretion. This disease, which is increasing in prevalence worldwide, is associated with both gout and metabolic diseases. Several studies have reported relationships between apolipoprotein E (APOE) haplotypes and SUA levels in humans; however, their results remain inconsistent. This prompted us to investigate the relationship between APOE polymorphisms and SUA levels. Our subjects were 5,272 Japanese men, premenopausal women, and postmenopausal women. Multiple linear regression analyses revealed the ε2 haplotype of APOE to be independently associated with higher SUA in men (N = 1,726) and postmenopausal women (N = 1,753), but not in premenopausal women (N = 1,793). In contrast, the ε4 haplotype was little related to SUA levels in each group. Moreover, to examine the effect of Apoe deficiency on SUA levels, we conducted animal experiments using Apoe knockout mice, which mimics ε2/ε2 carriers. We found that SUA levels in Apoe knockout mice were significantly higher than those in wild-type mice, which is consistent with the SUA-raising effect of the ε2 haplotype observed in our clinico-genetic analyses. Further analyses suggested that renal rather than intestinal underexcretion of urate could be involved in Apoe deficiency-related SUA increase. In conclusion, we successfully demonstrated that the ε2 haplotype, but not the ε4 haplotype, increases SUA levels. These findings will improve our understanding of genetic factors affecting SUA levels. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Porphyrin accumulation in humans with common dysfunctional variants of ABCG2, a porphyrin transporter: potential association with acquired photosensitivity.
- Author
-
Sakiyama, Masayuki, Matsuo, Hirotaka, Toyoda, Yu, Yonekura, Yuiko, Ishikawa, Takahiro, Nakayama, Akiyoshi, Higashino, Toshihide, Kawamura, Yusuke, Fujimoto, Norihiro, Shinomiya, Nariyoshi, and Satoh, Takahiro
- Subjects
PORPHYRINS ,PHOTOSENSITIVITY ,JAPANESE people ,SKIN cancer ,GENETIC variation ,ATP-binding cassette transporters - Abstract
Photosensitivity is a skin reaction disorder mediated by phototoxic and/or photoallergic mechanisms. The accumulation of porphyrins is generally considered to induce phototoxicity. ATP-binding cassette subfamily G member 2 (ABCG2) has been identified as a transporter of porphyrins and its common variants—p.Gln126Ter (rs72552713) and p.Gln141Lys (rs2231142)—reportedly decrease the function of porphyrin transport in vitro; however, the physiological importance of ABCG2 as a porphyrin transporter remains to be fully elucidated. We herein investigated whether ABCG2 dysfunction could lead to porphyrin accumulation and photosensitivity in Japanese subjects, and found it to be significantly correlated with erythrocyte protoporphyrin levels (P = 0.012). This appears to be the first clinical finding of ABCG2 dysfunction-associated protoporphyrin accumulation in humans. We divided the patients into a chronic actinic dermatosis (CAD) group and a non-CAD group. CAD was diagnosed based on the criteria of reduced minimal erythema doses to ultraviolet B (UVB) and/or ultraviolet A (UVA). The non-CAD group was composed of patients who exhibited normal reactions to UVB and UVA on phototesting, but had histories of recurrent erythema/papules on sun-exposed areas. Estimated ABCG2 function according to ABCG2 genotypes in the non-CAD group was significantly lower than in the general Japanese population (P = 0.045). In contrast, no difference was found in ABCG2 function between the CAD group and the general population, suggesting that ABCG2 dysfunction might be a genetic factor in non-CAD patients with clinical photosensitivity. In this context, genetic dysfunction of ABCG2 might be an overlooked pathological etiology of "photosensitivity of unknown cause." [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Inhibitory effect of Citrus flavonoids on the in vitro transport activity of human urate transporter 1 (URAT1/SLC22A12), a renal re-absorber of urate.
- Author
-
Toyoda, Yu, Takada, Tappei, Saito, Hiroki, Hirata, Hiroshi, Ota-Kontani, Ami, Kobayashi, Naoyuki, Tsuchiya, Youichi, and Suzuki, Hiroshi
- Subjects
FLAVONOIDS ,CITRUS ,TRANSPORTATION ,HYPERURICEMIA ,NARINGENIN - Abstract
As hyperuricemia is a cause of urate-related diseases such as gout, the anti-hyperuricemic and/or uricosuric activity of food ingredients is receiving increased attention. Here, we examined the inhibitory activities of seven Citrus flavonoids against URAT1, a renal transporter involved in urate re-uptake from urine. We found that naringenin and nobiletin strongly inhibited URAT1, and may therefore serve as an anti-hyperuricemic food ingredient that can reduce the risk of urate-related diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet.
- Author
-
Toyoda, Yu, Takada, Tappei, Yamanashi, Yoshihide, and Suzuki, Hiroshi
- Subjects
HIGH-fat diet ,FATTY liver ,FATTY degeneration ,BILE ,TRANSGENIC mice - Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide, although its pathogenesis remains to be elucidated. A recent study revealed that hepatic Niemann-Pick C1-Like 1 (NPC1L1), a cholesterol re-absorber from bile to the liver expressed on the bile canalicular membrane, is an exacerbation factor of NAFLD. Indeed, transgenic mice with hepatic expression of human NPC1L1 under a liver-specific promoter (L1-Tg mice) developed steatosis with a high-fat diet (HFD) containing cholesterol within a few weeks. However, the mechanism underlying diet-induced hepatic NPC1L1-mediated lipid accumulation is poorly defined. Methods: To achieve a deeper understanding of steatosis development in L1-Tg mice, the biochemical features of hepatic NPC1L1-mediated steatosis were investigated. Hemizygous L1-Tg mice and wild-type littermate controls fed a HFD or control-fat diet were used. At the indicated time points, the livers were evaluated for cholesterol and triglyceride (TG) contents as well as mRNA levels of hepatic genes involved in the maintenance of lipid homeostasis. The hepatic ability to secrete very low-density lipoprotein (VLDL)-TG was also investigated. Results: Unlike the livers of wild-type mice that have little expression of hepatic Npc1l1, the livers of L1-Tg mice displayed time-dependent changes that indicated steatosis formation. In steatosis, there were three different stages of development: mild accumulation of hepatic cholesterol and TG (early stage), acceleration of hepatic TG accumulation (middle stage), and further accumulation of hepatic cholesterol (late stage). In the early stage, between WT and L1-Tg mice fed a HFD for 2 weeks, there were no significant differences in the hepatic expression of Pparα, Acox1, Fat/Cd36, Srebf1, and Srebf2; however, the hepatic ability to secrete VLDL-TG decreased in L1-Tg mice (P < 0.05). Furthermore, this decrease was completely prevented by administration of ezetimibe, an NPC1L1-selective inhibitor. Conclusion: Hepatic NPC1L1 exacerbates diet-induced steatosis, which was accompanied by decreased hepatic ability of VLDL-TG secretion. The obtained results provide a deeper understanding of L1-Tg mice as a promising NAFLD animal model that is able to re-absorb biliary-secreted cholesterol similar to humans. Furthermore, this work supports further studies of the pathophysiological impact of re-absorbed biliary cholesterol on the regulation of hepatic lipid homeostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. An X chromosome-wide meta-analysis based on Japanese cohorts revealed that non-autosomal variations are associated with serum urate.
- Author
-
Nakatochi, Masahiro, Toyoda, Yu, Kanai, Masahiro, Nakayama, Akiyoshi, Kawamura, Yusuke, Hishida, Asahi, Mikami, Haruo, Matsuo, Keitaro, Takezaki, Toshiro, Momozawa, Yukihide, Project, The Biobank Japan, Kamatani, Yoichiro, Ichihara, Sahoko, Shinomiya, Nariyoshi, Yokota, Mitsuhiro, Wakai, Kenji, Okada, Yukinori, Matsuo, Hirotaka, and Urate), the Japan Uric Acid Genomics Consortium (Japan
- Subjects
CHROMOSOMES ,META-analysis ,GENETICS ,CONFIDENCE intervals ,SINGLE nucleotide polymorphisms ,GENETIC variation ,ALLELES ,SEX chromosomes ,SEX distribution ,GENE expression ,DESCRIPTIVE statistics ,URIC acid ,MITOGEN-activated protein kinases ,ODDS ratio - Abstract
The article discusses a study which investigated the contribution of genetic variations in the X chromosome to serum urate (SU) levels. Topics covered include the gender differences in the homeostasis of urate, the circulating form of uric acid, 12 single nucleotide polymorphisms (SNP) at the Xq28 locus that influence SU identified by the study, and the functional annotation of the newly identified locus in the context of SU.
- Published
- 2021
- Full Text
- View/download PDF
19. Identification of hepatic NPC1L1 as an NAFLD risk factor evidenced by ezetimibe‐mediated steatosis prevention and recovery.
- Author
-
Toyoda, Yu, Takada, Tappei, Umezawa, Masakazu, Tomura, Fumiya, Yamanashi, Yoshihide, Takeda, Ken, and Suzuki, Hiroshi
- Abstract
Non‐alcoholic fatty liver disease (NAFLD) is a serious global public health concern. Nevertheless, there are no specific medications for treating the associated abnormal accumulation of hepatic lipids such as cholesterol and triglycerides. While seminal findings suggest a link between hepatic cholesterol accumulation and NAFLD progression, the molecular bases of these associations are not well understood. Here, we experimentally demonstrate that hepatic Niemann‐Pick C1‐Like 1 (NPC1L1), a cholesterol re‐absorber from bile to the liver, can cause steatosis, an early stage of NAFLD using genetically engineered L1‐Tg mice characterized by hepatic expression of NPC1L1 under the control of ApoE promoter. Contrary to wild‐type mice that have little expression of hepatic Npc1l1, the livers of L1‐Tg mice fed a high‐fat diet became steatotic within only a few weeks. Moreover, hepatic NPC1L1‐mediated steatosis was not only prevented, but completely rescued, by orally administered ezetimibe, a well‐used lipid‐lowering drug on the global market, even under high‐fat diet feedings. These results indicate that hepatic NPC1L1 is an NAFLD‐exacerbating factor amendable to therapeutic intervention and would extend our understanding of the vital role of cholesterol uptake from bile in the development of NAFLD. Furthermore, administration of a TLR4 inhibitor also prevented the hepatic NPC1L1‐mediated steatosis formation, suggesting a latent link between physiological roles of hepatic NPC1L1 and regulation of innate immune system. Our results revealed that hepatic NPC1L1 is a novel NAFLD risk factor contributing to steatosis formation that is rescued by ezetimibe; additionally, our findings uncover feasible opportunities for repositioning drugs to treat NAFLD in the near future. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications.
- Author
-
Toyoda, Yu, Takada, Tappei, and Suzuki, Hiroshi
- Subjects
ATP-binding cassette transporters ,CANCER chemotherapy ,MULTIDRUG resistance ,P-glycoprotein ,CELL membranes ,MITOXANTRONE ,PROTEIN-tyrosine kinase inhibitors ,XENOBIOTICS - Abstract
The ATP-binding cassette transporter G2 (ABCG2; also known as breast cancer resistance protein, BCRP) has been suggested to be involved in clinical multidrug resistance (MDR) in cancer like other ABC transporters such as ABCB1 (P -glycoprotein). As an efflux pump exhibiting a broad substrate specificity localized on cellular plasma membrane, ABCG2 excretes a variety of endogenous and exogenous substrates including chemotherapeutic agents, such as mitoxantrone and several tyrosine kinase inhibitors. Moreover, in the normal tissues, ABCG2 is expressed on the apical membranes and plays a pivotal role in tissue protection against various xenobiotics. For this reason, ABCG2 is recognized to be an important determinant of the pharmacokinetic characteristics of its substrate drugs. Although the clinical relevance of reversing the ABCG2-mediated MDR has been inconclusive, an appropriate modulation of ABCG2 function during chemotherapy should logically enhance the efficacy of anti-cancer agents by overcoming the MDR phenotype and/or improving their pharmacokinetics. To confirm this possibility, considerable efforts have been devoted to developing ABCG2 inhibitors, although there is no clinically available substance for this purpose. As a clue for addressing this issue, this mini-review provides integrated information covering the technical backgrounds necessary to evaluate the ABCG2 inhibitory effects on the target compounds and a current update on the ABCG2 inhibitors. This essentially includes our recent findings, as we serendipitously identified febuxostat, a well-used agent for hyperuricemia as a strong ABCG2 inhibitor, that possesses some promising potentials. We hope that an overview described here will add value to further studies involving in the multidrug transporters. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Identification of a dysfunctional splicing mutation in the SLC22A12/URAT1 gene causing renal hypouricaemia type 1: a report on two families.
- Author
-
Kawamura, Yusuke, Toyoda, Yu, Ohnishi, Takuma, Hisatomi, Ryutaro, Higashino, Toshihide, Nakayama, Akiyoshi, Shimizu, Seiko, Yanagi, Masato, Kamimaki, Isamu, Fujimaru, Rika, Suzuki, Hiroshi, Shinomiya, Nariyoshi, Takada, Tappei, and Matsuo, Hirotaka
- Subjects
HYPERURICEMIA ,URIC acid - Abstract
In the article, the authors present two cases of Japanese families with inherited renal hypouricaemia (RHUC) linked with a functionally null variant in exon-intron boundary of the urate transporter 1 (URAT1) or SLC22A12 gene. Also cited are the RHUC complications like exercise-induced acute kidney injury and urolithiasis, as well as the link of URAT1 with serum uric acid (SUA) level.
- Published
- 2020
- Full Text
- View/download PDF
22. Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2.
- Author
-
Toyoda, Yu, Pavelcová, Kateřina, Klein, Martin, Suzuki, Hiroshi, Takada, Tappei, and Stiburkova, Blanka
- Published
- 2019
- Full Text
- View/download PDF
23. Human ABC Transporter ABCC11: Looking Back Pioneers' Odyssey and Creating a New Path Toward Clinical Application.
- Author
-
Ishikawa, Toshihisa and Toyoda, Yu
- Published
- 2016
- Full Text
- View/download PDF
24. Spontaneous Production of Glutathione-Conjugated Forms of 1,2-Dichloropropane: Comparative Study on Metabolic Activation Processes of Dihaloalkanes Associated with Occupational Cholangiocarcinoma.
- Author
-
Toyoda, Yu, Takada, Tappei, and Suzuki, Hiroshi
- Published
- 2017
- Full Text
- View/download PDF
25. Drugs Affecting Epigenetic Modifications of ABC Transporters for Drug Resistance.
- Author
-
Satake, Kazuhiro, Toyoda, Yu, and Nakagawa, Hiroshi
- Published
- 2015
- Full Text
- View/download PDF
26. Regulation of the Axillary Osmidrosis-Associated ABCC11 Protein Stability by N-Linked Glycosylation: Effect of Glucose Condition.
- Author
-
Toyoda, Yu, Takada, Tappei, Miyata, Hiroshi, Ishikawa, Toshihisa, and Suzuki, Hiroshi
- Subjects
ADENOSINE triphosphate ,CARRIER proteins ,CELL membranes ,LIPOPHILICITY ,GLYCANS - Abstract
ATP-binding cassette C11 (ABCC11) is a plasma membrane protein involved in the transport of a variety of lipophilic anions. ABCC11 wild-type is responsible for the high-secretion phenotypes in human apocrine glands, such as that of wet-type ear wax, and the risk of axillary osmidrosis. We have previously reported that mature ABCC11 is a glycoprotein containing two N-linked glycans at Asn838 and Asn844. However, little is known about the role of N-linked glycosylation in the regulation of ABCC11 protein. In the current study, we investigated the effects of N-linked glycosylation on the protein level and localization of ABCC11 using polarized Madin-Darby canine kidney II cells. When the N-linked glycosylation in ABCC11-expressing cells was chemically inhibited by tunicamycin treatment, the maturation of ABCC11 was suppressed and its protein level was significantly decreased. Immunoblotting analyses demonstrated that the protein level of the N-linked glycosylation-deficient mutant (N838Q and N844Q: Q838/844) was about half of the ABCC11 wild-type level. Further biochemical studies with the Q838/844 mutant showed that this glycosylation-deficient ABCC11 was degraded faster than wild-type probably due to the enhancement of the MG132-sensitive protein degradation pathway. Moreover, the incubation of ABCC11 wild-type-expressing cells in a low-glucose condition decreased mature, glycosylated ABCC11, compared with the high-glucose condition. On the other hand, the protein level of the Q838/844 mutant was not affected by glucose condition. These results suggest that N-linked glycosylation is important for the protein stability of ABCC11, and physiological alteration in glucose may affect the ABCC11 protein level and ABCC11-related phenotypes in humans, such as axillary osmidrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Prediction of Drug Transfer into Milk Considering Breast Cancer Resistance Protein (BCRP)-Mediated Transport.
- Author
-
Ito, Naoki, Ito, Kousei, Ikebuchi, Yuki, Toyoda, Yu, Takada, Tappei, Hisaka, Akihiro, Oka, Akira, and Suzuki, Hiroshi
- Subjects
DRUG analysis ,BREAST cancer treatment ,LACTATION ,IN vitro studies ,EPITHELIUM ,PHYSIOLOGY - Abstract
Purpose: Drug transfer into milk is of concern due to the unnecessary exposure of infants to drugs. Proposed prediction methods for such transfer assume only passive drug diffusion across the mammary epithelium. This study reorganized data from the literature to assess the contribution of carrier-mediated transport to drug transfer into milk, and to improve the predictability thereof. Methods: Milk-to-plasma drug concentration ratios (M/Ps) in humans were exhaustively collected from the literature and converted into observed unbound concentration ratios (M/P). The ratios were also predicted based on passive diffusion across the mammary epithelium (M/P). An in vitro transport assay was performed for selected drugs in breast cancer resistance protein (BCRP)-expressing cell monolayers. Results: M/P and M/P values were compared for 166 drugs. M/P values were 1.5 times or more higher than M/P values for as many as 13 out of 16 known BCRP substrates, reconfirming BCRP as the predominant transporter contributing to secretory transfer of drugs into milk. Predictability of M/P values for selected BCRP substrates and non-substrates was improved by considering in vitro-evaluated BCRP-mediated transport relative to passive diffusion alone. Conclusions: The current analysis improved the predictability of drug transfer into milk, particularly for BCRP substrates, based on an exhaustive data overhaul followed by focused in vitro transport experimentation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. Production of Cells with Targeted Integration of Gene Variants of Human ABC Transporter for Stable and Regulated Expression Using the Flp Recombinase System.
- Author
-
Wakabayashi-Nakao, Kanako, Tamura, Ai, Koshiba, Shoko, Toyoda, Yu, Nakagawa, Hiroshi, and Ishikawa, Toshihisa
- Published
- 2010
- Full Text
- View/download PDF
29. Identification of Inhibitory Activities of Dietary Flavonoids against URAT1, a Renal Urate Re-Absorber: In Vitro Screening and Fractional Approach Focused on Rooibos Leaves.
- Author
-
Toyoda, Yu, Takada, Tappei, Saito, Hiroki, Hirata, Hiroshi, Ota-Kontani, Ami, Tsuchiya, Youichi, and Suzuki, Hiroshi
- Abstract
Hyperuricemia, a lifestyle-related disease characterized by elevated serum urate levels, is the main risk factor for gout; therefore, the serum urate-lowering effects of human diets or dietary ingredients have attracted widespread interest. As Urate transporter 1 (URAT1) governs most urate reabsorption from primary urine into blood, URAT1 inhibition helps decrease serum urate levels by increasing the net renal urate excretion. In this study, we used a cell-based urate transport assay to investigate the URAT1-inhibitory effects of 162 extracts of plant materials consumed by humans. Among these, we focused on Aspalathus linearis, the source of rooibos tea, to explore its active ingredients. Using liquid–liquid extraction with subsequent column chromatography, as well as spectrometric analyses for chemical characterization, we identified quercetin as a URAT1 inhibitor. We also investigated the URAT1-inhibitory activities of 23 dietary ingredients including nine flavanols, two flavanonols, two flavones, two isoflavonoids, eight chalcones, and a coumarin. Among the tested authentic chemicals, fisetin and quercetin showed the strongest and second-strongest URAT1-inhibitory activities, with IC
50 values of 7.5 and 12.6 μM, respectively. Although these effects of phytochemicals should be investigated further in human studies, our findings may provide new clues for using nutraceuticals to promote health. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
30. Febuxostat inhibited axillary osmidrosis risk factor ATP‐binding cassette transporter C11 in vitro.
- Author
-
Toyoda, Yu, Takada, Tappei, and Suzuki, Hiroshi
- Published
- 2020
- Full Text
- View/download PDF
31. Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2.
- Author
-
Nakagawa, Hiroshi, Wakabayashi-Nakao, Kanako, Tamura, Ai, Toyoda, Yu, Koshiba, Shoko, and Ishikawa, Toshihisa
- Subjects
GLYCOSYLATION ,ESTERIFICATION ,CELL membranes ,UBIQUITIN ,IMMUNOCYTOCHEMISTRY ,ANTIVIRAL agents ,MEMBRANE proteins - Abstract
The human ATP-binding cassette (ABC) transporter, ABCG2 (BCRP/MXR/ABCP), is a plasma membrane protein containing intramolecular and intermolecular disulfide bonds and an N-linked glycan at Asn596. We have recently reported that the intramolecular disulfide bond is a critical checkpoint for determining the degradation fates of ABCG2. In the present study, we aimed to analyze quantitatively the impact of the N-linked glycan on the protein stability of ABCG2. For this purpose, we incorporated one single copy of ABCG2 cDNA into a designated site of genomic DNA in Flp-In-293 cells to stably express ABCG2 or its variant proteins. When ABCG2 wild type-expressing cells were incubated with various N-linked glycosylation inhibitors, tunicamycin profoundly suppressed the protein expression level of ABCG2 and, accordingly, reduced the ABCG2-mediated cellular resistance to the cancer chemotherapeutic SN-38. When Asn596 was converted to Gln596, the resulting variant protein was not glycosylated, and its protein level was about one-third of the wild type level in Flp-In-293 cells. Treatment with MG132, a proteasome inhibitor, increased the level of the variant protein. Immunoblotting with anti-ubiquitin IgG1k after immunoprecipitation of ABCG2 revealed that the N596Q protein was ubiquitinated at levels that were significantly enhanced by treatment with MG132. Immunofluorescence microscopy demonstrated that treatment with MG132 increased the level of ABCG2 N596Q protein both in intracellular compartments and in the plasma membrane. In conclusion, we propose that the N-linked glycan at Asn596 is important for stabilizing de novo-synthesized ABCG2 and that disruption of this linkage results in protein destabilization and enhanced ubiquitin-mediated proteasomal degradation. Structured digital abstract • , : ABCG2 (uniprotkb: ) physically interacts ( ) with Ubiquitin (uniprotkb: ) by anti bait coimmunoprecipitation ( ) [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
32. Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter ABCC11 gene determine earwax type?
- Author
-
Toyoda, Yu, Sakurai, Aki, Mitani, Yasumasa, Nakashima, Masahiro, Yoshiura, Koh-ichiro, Nakagawa, Hiroshi, Sakai, Yasuo, Ota, Ikuko, Lezhava, Alexander, Hayashizaki, Yoshihide, Niikawa, Norio, and Ishikawa, Toshihisa
- Subjects
GENETIC polymorphisms ,NUCLEOTIDES ,GLYCOSYLATION ,PROTEIN folding ,ENDOPLASMIC reticulum ,EARWAX - Abstract
One single-nucleotide polymorphism (SNP), 538G>A (Glyl80Arg), in the ABCC11 gene determines the type of earwax. The G/G and G/A genotypes correspond to the wet type of earwax, whereas A/A corresponds to the dry type. Wide ethnic differences exist in the frequencies of those alleles, reflecting global migratory waves of the ancestors of humankind. We herein provide the evidence that this genetic polymorphism has an effect on the N-linked glycosylation of ABCC11, intracellular sorting, and proteasomal degradation of the variant protein. Immunohistochemical studies with cerumen gland-containlng tissue specimens revealed that the ABCC11 WT protein was localized in intracellular granules and large vacuoles, as well as at the luminal membrane of secretory cells in the cerumen gland, whereas granular or vacuolar localization was not detected for the SNP (Arg180) variant. This SNP variant lacking N-linked glycosylation is recognized as a misfolded protein in the endoplasmic reticulum and readily undergoes ubiquitinalion and proteasomal degradation, which determines the dry type of earwax as a mendelian trait with a recessive phenotype. For rapid genetic diagnosis of axillary osmidrosis and potential risk of breast cancer, we developed specific primers for the SmartAmp method that enabled us to clinically genotype the ABCC11 gene within 30 min. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
33. A Proposal for Practical Diagnosis of Renal Hypouricemia: Evidenced from Genetic Studies of Nonfunctional Variants of URAT1/SLC22A12 among 30,685 Japanese Individuals.
- Author
-
Kawamura, Yusuke, Nakayama, Akiyoshi, Shimizu, Seiko, Toyoda, Yu, Nishida, Yuichiro, Hishida, Asahi, Katsuura-Kamano, Sakurako, Shibuya, Kenichi, Tamura, Takashi, Kawaguchi, Makoto, Suzuki, Satoko, Iwasawa, Satoko, Nakashima, Hiroshi, Ibusuki, Rie, Uemura, Hirokazu, Hara, Megumi, Takeuchi, Kenji, Takada, Tappei, Tsunoda, Masashi, and Arisawa, Kokichi
- Subjects
URIC acid ,MULTIPLE regression analysis ,GENETIC variation ,GENETIC testing - Abstract
Background: Renal hypouricemia (RHUC) is characterized by a low serum uric acid (SUA) level and high fractional excretion of uric acid (FE
UA ). Further studies on FEUA in hypouricemic individuals are needed for a more accurate diagnosis of RHUC. Methods: In 30,685 Japanese health-examination participants, we genotyped the two most common nonfunctional variants of URAT1 (NFV-URAT1), W258X (rs121907892) and R90H (rs121907896), in 1040 hypouricemic individuals (SUA ≤ 3.0 mg/dL) and 2240 individuals with FEUA data. The effects of NFV-URAT1 on FEUA and SUA were also investigated using linear and multiple regression analyses. Results: Frequency of hypouricemic individuals (SUA ≤ 3.0 mg/dL) was 0.97% (male) and 6.94% (female) among 30,685 participants. High frequencies of those having at least one allele of NFV-URAT1 were observed in 1040 hypouricemic individuals. Furthermore, NFV-URAT1 significantly increased FEUA and decreased SUA, enabling FEUA and SUA levels to be estimated. Conversely, FEUA and SUA data of hypouricemic individuals are revealed to be useful to predict the number of NFV-URAT1. Conclusions: Our findings reveal that specific patterns of FEUA and SUA data assist with predicting the number of nonfunctional variants of causative genes for RHUC, and can also be useful for practical diagnosis of RHUC even before genetic tests. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
34. Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.
- Author
-
Toyoda, Yu, Pavelcová, Kateřina, Bohatá, Jana, Ješina, Pavel, Kubota, Yu, Suzuki, Hiroshi, Takada, Tappei, Stiburkova, Blanka, and Falguières, Thomas
- Subjects
GOUT ,HYPERURICEMIA ,URIC acid ,CHILD patients ,DIAGNOSIS ,PHENOTYPES - Abstract
The ABCG2 gene is a well-established hyperuricemia/gout risk locus encoding a urate transporter that plays a crucial role in renal and intestinal urate excretion. Hitherto, p.Q141K—a common variant of ABCG2 exhibiting approximately one half the cellular function compared to the wild-type—has been reportedly associated with early-onset gout in some populations. However, compared with adult-onset gout, little clinical information is available regarding the association of other uricemia-associated genetic variations with early-onset gout; the latent involvement of ABCG2 in the development of this disease requires further evidence. We describe a representative case of familial pediatric-onset hyperuricemia and early-onset gout associated with a dysfunctional ABCG2, i.e., a clinical history of three generations of one Czech family with biochemical and molecular genetic findings. Hyperuricemia was defined as serum uric acid (SUA) concentrations 420 μmol/L for men or 360 μmol/L for women and children under 15 years on two measurements, performed at least four weeks apart. The proband was a 12-year-old girl of Roma ethnicity, whose SUA concentrations were 397–405 µmol/L. Sequencing analyses focusing on the coding region of ABCG2 identified two rare mutations—c.393G>T (p.M131I) and c.706C>T (p.R236X). Segregation analysis revealed a plausible link between these mutations and hyperuricemia and the gout phenotype in family relatives. Functional studies revealed that p.M131I and p.R236X were functionally deficient and null, respectively. Our findings illustrate why genetic factors affecting ABCG2 function should be routinely considered in clinical practice as part of a hyperuricemia/gout diagnosis, especially in pediatric-onset patients with a strong family history. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: In Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary Flavonoids.
- Author
-
Saito, Hiroki, Toyoda, Yu, Hirata, Hiroshi, Ota-Kontani, Ami, Tsuchiya, Youichi, Takada, Tappei, and Suzuki, Hiroshi
- Abstract
Axillary osmidrosis (AO) is a common chronic skin condition characterized by unpleasant body odors emanating from the armpits, and its aetiology is not fully understood. AO can seriously impair the psychosocial well-being of the affected individuals; however, no causal therapy has been established for it other than surgical treatment. Recent studies have revealed that human ATP-binding cassette transporter C11 (ABCC11) is an AO risk factor when it is expressed in the axillary apocrine glands—the sources of the offensive odors. Hence, identifying safe ways to inhibit ABCC11 may offer a breakthrough in treating AO. We herein screened for ABCC11-inhibitory activities in 34 natural products derived from plants cultivated for human consumption using an in vitro assay system to measure the ABCC11-mediated transport of radiolabeled dehydroepiandrosterone sulfate (DHEA-S—an ABCC11 substrate). The water extract of soybean (Glycine max) was found to exhibit the strongest transport inhibition. From this extract, via a fractionation approach, we successfully isolated and identified genistein, a soy isoflavone, as a novel ABCC11 inhibitor with a half-maximal inhibitory concentration value of 61.5 μM. Furthermore, we examined the effects of other dietary flavonoids on the ABCC11-mediated DHEA-S transport to uncover the effects of these phytochemicals on ABCC11 function. While further human studies are needed, our findings here about the natural compounds will help develop a non-surgical therapy for AO. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Omega-3 Polyunsaturated Fatty Acids Inhibit the Function of Human URAT1, a Renal Urate Re-absorber.
- Author
-
Saito, Hiroki, Toyoda, Yu, Takada, Tappei, Hirata, Hiroshi, Ota-Kontani, Ami, Miyata, Hiroshi, Kobayashi, Naoyuki, Tsuchiya, Youichi, and Suzuki, Hiroshi
- Abstract
The beneficial effects of fatty acids (FAs) on human health have attracted widespread interest. However, little is known about the impact of FAs on the handling of urate, the end-product of human purine metabolism, in the body. Increased serum urate levels occur in hyperuricemia, a disease that can lead to gout. In humans, urate filtered by the glomerulus of the kidney is majorly re-absorbed from primary urine into the blood via the urate transporter 1 (URAT1)-mediated pathway. URAT1 inhibition, thus, contributes to decreasing serum urate concentration by increasing net renal urate excretion. Here, we investigated the URAT1-inhibitory effects of 25 FAs that are commonly contained in foods or produced in the body. For this purpose, we conducted an in vitro transport assay using cells transiently expressing URAT1. Our results showed that unsaturated FAs, especially long-chain unsaturated FAs, inhibited URAT1 more strongly than saturated FAs. Among the tested unsaturated FAs, eicosapentaenoic acid, α-linolenic acid, and docosahexaenoic acid exhibited substantial URAT1-inhibitory activities, with half maximal inhibitory concentration values of 6.0, 14.2, and 15.2 μM, respectively. Although further studies are required to investigate whether the ω-3 polyunsaturated FAs can be employed as uricosuric agents, our findings further confirm FAs as nutritionally important substances influencing human health. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort.
- Author
-
Toyoda, Yu, Mančíková, Andrea, Krylov, Vladimír, Morimoto, Keito, Pavelcová, Kateřina, Bohatá, Jana, Pavelka, Karel, Pavlíková, Markéta, Suzuki, Hiroshi, Matsuo, Hirotaka, Takada, Tappei, and Stiburkova, Blanka
- Subjects
GOUT ,HYPERURICEMIA ,CELL membranes ,FUNCTIONAL analysis ,DISEASE risk factors - Abstract
ATP-binding cassette subfamily G member 2 (ABCG2) is a physiologically important urate transporter. Accumulating evidence demonstrates that congenital dysfunction of ABCG2 is an important genetic risk factor in gout and hyperuricemia; recent studies suggest the clinical significance of both common and rare variants of ABCG2. However, the effects of rare variants of ABCG2 on the risk of such diseases are not fully understood. Here, using a cohort of 250 Czech individuals of European descent (68 primary hyperuricemia patients and 182 primary gout patients), we examined exonic non-synonymous variants of ABCG2. Based on the results of direct sequencing and database information, we experimentally characterized nine rare variants of ABCG2: R147W (rs372192400), T153M (rs753759474), F373C (rs752626614), T421A (rs199854112), T434M (rs769734146), S476P (not annotated), S572R (rs200894058), D620N (rs34783571), and a three-base deletion K360del (rs750972998). Functional analyses of these rare variants revealed a deficiency in the plasma membrane localization of R147W and S572R, lower levels of cellular proteins of T153M and F373C, and null urate uptake function of T434M and S476P. Accordingly, we newly identified six rare variants of ABCG2 that showed lower or null function. Our findings contribute to deepening the understanding of ABCG2-related gout/hyperuricemia risk and the biochemical characteristics of the ABCG2 protein. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.